Industry Update: Capital market and finances

Written by Dusko ILIC

Capital marker and finance developments compiled from 1—31 July 2015

Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions 1—31 July 2015, scheduled to be published in Volume 10 Issue 8 of Regenerative Medicine.


BioCardia (CA, USA; filed an amended S-1 form with the Securities and Exchange Commission (SEC) regarding its initial public offering. In this filing the company gave its expected price range as US$ 12 to US$ 14 for about 3.85 million shares. At the maximum price this offering is valued at roughly US$ 53.9 million. The company intends to list on the NASDAQ Global Market under the symbol BCDA.


Caladrius Biosciences(NY, USA; has received notice of an award from the National Eye Institute of the National Institutes of Health (MD, USA; for a project to investigate 3D retinal constructs for vision restoration in patients with age-related macular degeneration (Award Number R01EY024045). The total planned amount the grant is US$ 671,633.


ReNeuron (UK; has raised a total of US$ 106.7 (£68.4) million, before expenses, through a conditional placing of 1,367,411,939 new ordinary shares at a price of 5p per share.